TABLE 4.
Effect Size of PRO Instruments Between Study Time Periodsa
| Baseline to 6 Weeks | 6 Weeks to 6 Months | |||
|---|---|---|---|---|
| Instrument | Effect Size (95% CI) | SRM (95% CI) | Effect Size (95% CI) | SRM (95% CI) |
| EQ-5D | 0.36b (0.19 to 0.53) | 0.357 (0.18 to 0.53) | 1.15d (0.92 to 1.38) | 1.009 (0.78 to 1.23) |
| KOOS-ADL | 0.50c (0.28 to 0.70) | 0.405 (0.19 to 0.61) | 1.51d (1.24 to 1.78) | 1.201 (0.95 to 1.48) |
| KOOS-sport | 0.34b (0.13 to 0.55) | 0.274 (0.06 to 0.48) | 1.53d (1.25 to 1.80) | 1.204 (0.95 to 1.45) |
| KOOS-QOL | 0.41b (0.24 to 0.58) | 0.402 (0.23 to 0.57) | 1.22d (0.99 to 1.46) | 1.098 (0.87 to 1.32) |
| SF-36 PF | 0.07b (–0.12 to 0.25) | 0.057 (–0.13 to 0.24) | 1.37d (1.10 to 1.64) | 1.050 (0.80 to 1.29) |
| PROMIS PF CAT | 0.12b (–0.07 to 0.31) | 0.100 (–0.09 to 0.29) | 1.43d (1.17 to 1.69) | 1.197 (0.95 to 1.44) |
aADL, activities of daily living; EQ-5D, EuroQol–5 dimensions questionnaire; KOOS, Knee injury and Osteoarthritis Outcome Score; MARS, Marx Activity Rating Scale; PF, physical function; PRO, patient-reported outcome; PROMIS PF CAT, Patient-Reported Outcomes Measurement Information System physical function computer adaptive test; QOL, quality of life; SF-36, Short Form–36 Health Survey; SRM, standardized response mean.
bSmall effect size.
cMedium effect size.
dLarge effect size.